Verastem | VSTM - Operating Expenses


Verastem reported $37.03M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alaunos Therapeutics USD 1.19M 428K Sep/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Curis USD -13.99M 7.38M Jun/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Laboratory Of America USD 3.13B 32.4M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Verastem USD 37.03M 8.97M Sep/2024